奥沙利铂联合羟基喜树碱治疗晚期胃癌临床分析

背景与目的体外及体内的临床研究显示,奥沙利铂(L-OHP)对多种肿瘤有显著抑制作用并与绝大多数抗癌药物具有相加或协同细胞毒作用.本文旨在观察L-OHP联合羟基喜树碱(HCPT)治疗晚期胃癌的近期疗效和患者耐受性,并与传统的化疗方案进行对比.方法采用非随机的分组方法将43例晚期胃癌患者分为L-OHP+HCPT方案组(治疗组)与Vp-16+CF+5-FU(ELF)方案组(对照组),其中男性28例,女性15例,中位年龄59岁,KPS评分≥60,观察两组的近期疗效和患者耐受性.结果治疗组24例有效率58.3%(14/24),对照组19例有效率42.1%(8/19).治疗组有效率高于对照组,两组差异有显著性(P<0.05).两组不良反应主要是骨髓抑制、恶心、呕吐、口腔炎、周围神经炎、静脉炎、脱发等,均在Ⅰ、Ⅱ度范围内.结论L-OHP联合HCPT方案治疗晚期胃癌疗效较好,不良反应可以耐受.

Clinical study on patients with advanced gastric cancer treated with oxaliplatin combining with hydroxycamptothecine

BACKGROUND AND OBJECTIVE: Internal and external physiological research showed oxaliplatin could obviously suppress several kinds of tumors in combination with most anti-cancer drugs and help these drugs to kill the tumor cells. This study was designed to investigate the initial curative effects and tolerance of patients with advanced gastric cancer of treatment with combination of oxaliplatin (L-OHP) and hydroxycamptothecine (HCPT). We compared this treatment with traditional chemotherapy. METHODS: In a non-randomized manner, 43 patients with advanced gastric cancer were divided into treatment group (L-OHP plus HCPT) and control group (VP-16 + CF + 5-FU) (ELF). Among these patients, 28 were male and 15 were female. The median age was 59. Karnofsky performance status(KPS) scale was more than 60. We compared the initial curative effects and tolerance between these two groups. RESULTS: The beneficial effects for the treatment group (24 cases) and control group (19 cases) were 58.3% (14/24) and 42.1% (8/19), respectively. Obviously, the beneficial effects to the treatment group were higher than that of the control group (P < 0.05). The side effects of both groups included bone marrow suppression, nausea, vomiting, stomatitis, neuritis, phlebitis, hair loss, and so on. But they were slight (within I and II degree). CONCLUSIONS: The use of L-OHP plus HCPT appears to be a very good treatment for patients with advanced gastric cancer. The patients can tolerate the side effects.